Crenessity CAH denied as non-formulary by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for crenessity cah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Crenessity for CAH as Non-Formulary — and Why You Can Appeal

Blue Cross Blue Shield formularies tier drugs based on cost, availability of alternatives, and clinical review. Crenessity (tildacerfont) is a recently approved agent for congenital adrenal hyperplasia and may not yet appear on all BCBS formularies, or may be placed on a specialty tier with a coverage exclusion. A non-formulary denial means the plan will not pay at any tier without a granted formulary exception.

Formulary exceptions exist precisely for situations where no formulary alternative is clinically appropriate. For a condition as specific as CAH — where Crenessity's mechanism of reducing ACTH-driven androgen excess is distinct from the glucocorticoids already on formulary — a formulary exception request supported by strong clinical documentation is often viable.

## Federal Appeal Rights

• ACA §2719 external review: After your internal formulary exception request and appeal are exhausted, you may request independent external review. The standard window is approximately four months from the final internal denial — verify the exact deadline on your denial letter.
• ERISA §503: If you have an employer-sponsored plan, you are entitled to written identification of the specific formulary alternative(s) the plan considered equivalent, and the basis for that classification.

## Concrete Appeal Steps

1. Request a formulary exception in writing. Ask BCBS to identify the on-formulary alternatives it considers therapeutically equivalent to Crenessity for CAH and to provide its formulary exception criteria. 2. Obtain your prescriber's letter addressing each formulary alternative the plan identifies. The letter should explain, for each alternative, why it is not clinically equivalent for this patient — referencing chart-documented history, mechanism of action differences, or documented prior outcomes — without fabricating statistics. 3. Gather clinical documentation: CAH diagnosis confirmation, current and prior treatment history with dates and clinical outcomes from the chart, and endocrinology notes documenting clinical status. 4. File the formulary exception and, if denied, the internal appeal, within the plan's stated deadlines.

## Criteria-Mapping Structure

| Formulary Exception Criterion | Your Supporting Documentation | |---|---| | No formulary alternative is clinically appropriate | Prescriber letter addressing each named alternative | | Formulary alternatives previously tried and failed | Chart records with dates and documented outcomes | | Formulary alternative is contraindicated or not tolerated | Prescriber letter citing clinical basis (from chart) | | Confirmed diagnosis for which Crenessity is indicated | Diagnostic records and FDA label confirming indication |

Obtain the exact current BCBS formulary exception policy and the list of alternatives the plan considers equivalent before filing, so your prescriber's letter directly addresses each one.